J&J wins CE mark for stroke tech; ItriCon eyes layoffs;

 @FierceMedDev: MC10 pushes wearable sensors with Medtronic co-sign. News | Follow @FierceMedDev

 @DamianFierce: ICYMI: Startup NeuroTronik raised $13.1M to develop a neuromodulation solution for heart failure. News | Follow @DamianFierce

 @MarkHFierce: Nearly $10M in new financing will help Veniti gain CE marking for vein treatment devices. Report | Follow @MarkHFierce

> Codman Neuro, a division of Johnson & Johnson ($JNJ), won a CE marking for Revive SE, a next-generation self-expanding clot removal device to treat acute ischemic stroke. Item

> Industry insiders are generally optimistic about the Myriad Genetics ($MYGN) ruling that determined no company can patent human genes isolated from the bloodstream. Story

> SV Bio won CLIA certification for its California computational laboratory, which performs gene sequencing-based diagnostics tests. News

> CryoLife bought Hemosphere last month and now the company's HerRO graft system to treat end-stage renal disease hemodialysis patients has obtained a CE mark. Item

> IntriCon, which makes hearing aids and various medical devices, said it will lay off 35 people out of its 569-employee workforce. Item

> Surgical robots are growing in popularity, The Pittsburgh Business Times reports. Item (sub. req.)

Biotech News

 @FierceBiotech: From FierceBiomarkers.com : Brain scan may provide biomarker guideposts to ideal depression treatment. Article | Follow @FierceBiotech

 @JohnCFierce: Look for early competition on hep C: Gilead 1, AbbVie in photo finish 2; BMS 3. As ranked by BloombergReport | Follow @JohnCFierce

 @RyanMFierce: AbbVie: We can beat Gilead in blockbuster hep C race. Report | Follow @RyanMFierce

 @EmilyMFierce: This week's roundup of hirings and new appointments in biopharma is here. | Follow @EmilyMFierce

> AbbVie: We can beat Gilead in blockbuster hep C race. Story

> Elan shares jump on news of sale process for the biotech. Report

> Eli Lilly racks up another Alzheimer's failure after BACE drug sparks safety fears. Article

Pharma News

 @FiercePharma: Come join our new LinkedIn group to connect with others in the industry and read, share and discuss the latest news. Join the group | Follow @FiercePharma

 @EricPFierce: FDA approves Amgen's Xgeva for bone tumor. It is a small market for a key drug that is not yet a blockbuster. Press release | Follow @EricPFierce

 @CarlyHFierce: Gleevec patent battle between Novartis and Sun Pharma moving to the U.S. Yesterday's story | Follow @CarlyHFierce

> AbbVie says it could beat Gilead to huge market for hep C drugs. More

> Wockhardt gets kicked in the gut again. Report

> Pfizer's potential stars Eliquis, Xeljanz see sluggish sales. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.